CIK 0001776111 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
MBX Biosciences, Inc.
Sign in to watch- Ticker
- MBX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 3179893100
- Business address
- 11711 N. MERIDIAN STREET, SUITE 300, CARMEL, IN, 46032
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $288,361
- in 2 filings
Net −$288,361. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-09-16 | New Enterprise Associates 17, L.P. 10% owner | Conversion · Series A Convertible Preferred Stock | −12,299,854 | 0 | ||
| 2024-09-16 | New Enterprise Associates 17, L.P. 10% owner | Conversion · Series B Convertible Preferred Stock | −25,142,840 | 0 | ||
| 2024-09-16 | Frazier Life Sciences X, L.P. 10% owner | Conversion | +3,927,774 | 3,927,774 | ||
| 2024-09-16 | Frazier Life Sciences X, L.P. 10% owner | Purchase | +625,000 | $16.00 | $10.0M | 4,552,774 |
| 2024-09-16 | Frazier Life Sciences X, L.P. 10% owner | Conversion · Series A Convertible Preferred Stock | −18,922,852 | 0 | ||
| 2024-09-16 | Frazier Life Sciences X, L.P. 10% owner | Conversion · Series B Convertible Preferred Stock | −28,297,265 | 0 | ||
| 2024-09-16 | CORNELIUS JAMES M Director | Conversion | +102,082 | 102,082 | ||
| 2024-09-16 | CORNELIUS JAMES M Director | Conversion · Series A Convertible Preferred Stock | −994,069 | 0 | ||
| 2024-09-16 | CORNELIUS JAMES M Director | Conversion · Series B Convertible Preferred Stock | −233,192 | 0 | ||
| 2024-09-16 | Heron Patrick J Director | Conversion | +3,927,774 | 3,927,774 | ||
| 2024-09-16 | Heron Patrick J Director | Purchase | +625,000 | $16.00 | $10.0M | 4,552,774 |
| 2024-09-16 | Heron Patrick J Director | Conversion · Series A Convertible Preferred Stock | −18,922,852 | 0 | ||
| 2024-09-16 | Heron Patrick J Director | Conversion · Series B Convertible Preferred Stock | −28,297,265 | 0 | ||
| 2024-09-16 | Hawryluk P. Kent President & CEO | Conversion | +283,846 | 481,397 | ||
| 2024-09-16 | Hawryluk P. Kent President & CEO | Conversion | +115,914 | 398,277 | ||
| 2024-09-16 | Hawryluk P. Kent President & CEO | Conversion · Series A Convertible Preferred Stock | −2,015,681 | 0 | ||
| 2024-09-16 | Hawryluk P. Kent President & CEO | Conversion · Series A Convertible Preferred Stock | −345,705 | 0 | ||
| 2024-09-16 | Hawryluk P. Kent President & CEO | Conversion · Series B Convertible Preferred Stock | −1,396,762 | 0 | ||
| 2024-09-16 | Hawryluk P. Kent President & CEO | Conversion · Series B Convertible Preferred Stock | −76,969 | 0 | ||
| 2024-09-16 | Hawryluk P. Kent President & CEO | Conversion · Series C Convertible Preferred Stock | −970,873 | 0 |
Page 7 of 9 · 164 trades